NCT00002286已完成不适用
Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study
Glaxo Wellcome2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.
- •Prior Medication:
- •Zidovudine (AZT).
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •Presence of any active opportunistic infection.
- •Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
- •Known hypersensitivity to zidovudine (AZT).
- •Impaired renal function.
- •Significant hepatic dysfunction.
- •Concurrent Medication:
- •- Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible).
- •Patients with the following are excluded:
- •Presence of any active opportunistic infection.
- •Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
- •Known hypersensitivity to zidovudine (AZT).
- •Impaired renal function.
- •Significant hepatic dysfunction.
- •Prior Medication:
- •Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine).
- •Excluded within 2 weeks of study entry:
- •Topical steroid, anthralin, or tar preparations.
- •Any other experimental therapy drugs which cause significant bone marrow suppression such as antifolates or pyrimethamine.
- •Cytolytic chemotherapy.
- •Drugs which cause significant nephrotoxicity or hepatotoxicity.
- •Rifampin or rifampin derivatives.
- •Excluded within 4 weeks of study entry:
- •Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy.
- •Excluded within 8 weeks of study entry:
- •Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Treatment of Psoriasis Using Acitretin in HIV-Positive PatientsPsoriasisHIV InfectionsNCT00002143Hoffmann-La Roche30
已完成
不适用
The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous SystemHIV InfectionsNCT00002288Glaxo Wellcome
已完成
不适用
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal FailureHIV InfectionsKidney Failure, ChronicNCT00002047Glaxo Wellcome
已完成
4 期
Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant PsoriasisPsoriasisNCT01356004Cairo University35
已完成
不适用
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)Lymphatic DiseaseHIV InfectionsNCT00002048Glaxo Wellcome